List/Grid

Oncology Subscribe to Oncology

Moving toward quality patient-centered care at cancer hospital

Moving toward quality patient-centered care at cancer hospital

In order to meet new cancer program accreditation standards, institutions have placed new focus on patient navigation, psychosocial distress screening, and survivorship care plans. Recently published research by the George Washington University (GW) Cancer Institute found these new programs are experiencing “growing pains.” The results of a nationwide survey conducted by the GW Cancer Institute and reviewed in the Journal of Oncology Navigation and Survivorship , found that health care professionals could most benefit from greater evaluation of their program’s impact Continue reading

Moving toward quality patient-centered care at cancer hospital

Moving toward quality patient-centered care at cancer hospital

In order to meet new cancer program accreditation standards, institutions have placed new focus on patient navigation, psychosocial distress screening, and survivorship care plans. Recently published research by the George Washington University (GW) Cancer Institute found these new programs are experiencing “growing pains.” The results of a nationwide survey conducted by the GW Cancer Institute and reviewed in the Journal of Oncology Navigation and Survivorship , found that health care professionals could most benefit from greater evaluation of their program’s impact. “This national study from GW Cancer Institute’s Center for the Advancement of Cancer Survivorship, Navigation and Policy provides insights into current approaches and barriers for patient-centered care in practice,” said Mandi Pratt-Chapman, M.A., director of the GW Cancer Institute Continue reading

Worry, behavior among teens at higher risk for breast cancer: Focus of new study

Worry, behavior among teens at higher risk for breast cancer: Focus of new study

Teenage girls with a familial or genetic risk for breast cancer worry more about getting the disease, even when their mother has no history, compared to girls their age with no known high risks, according to new data presented today by researchers from Penn Medicine’s Abramson Cancer Center at the annual meeting of the American Society of Clinical Oncology (ASCO) in Chicago. Early analyses suggest that such worry may increase risk behavior, such as smoking and potentially alcohol use, but does not appear to influence positive behavior, such as exercise. Continue reading

Worry, behavior among teens at higher risk for breast cancer: Focus of new study

Worry, behavior among teens at higher risk for breast cancer: Focus of new study

Teenage girls with a familial or genetic risk for breast cancer worry more about getting the disease, even when their mother has no history, compared to girls their age with no known high risks, according to new data presented today by researchers from Penn Medicine’s Abramson Cancer Center at the annual meeting of the American Society of Clinical Oncology (ASCO) in Chicago. Early analyses suggest that such worry may increase risk behavior, such as smoking and potentially alcohol use, but does not appear to influence positive behavior, such as exercise Continue reading

Long-term results encouraging for combination immunotherapy for advanced melanoma

Long-term results encouraging for combination immunotherapy for advanced melanoma

The first long-term follow-up results from a phase 1b immunotherapy trial combining drugs for advanced melanoma patients has shown encouraging results — long-lasting with high survival rates — researchers report. First author Mario Sznol, M.D., professor of medical oncology at Yale Cancer Center, is presenting the updated data at the 2014 annual conference of the American Society of Clinical Oncology (ASCO) in Chicago Continue reading

Long-term results encouraging for combination immunotherapy for advanced melanoma

Long-term results encouraging for combination immunotherapy for advanced melanoma

The first long-term follow-up results from a phase 1b immunotherapy trial combining drugs for advanced melanoma patients has shown encouraging results — long-lasting with high survival rates — researchers report. First author Mario Sznol, M.D., professor of medical oncology at Yale Cancer Center, is presenting the updated data at the 2014 annual conference of the American Society of Clinical Oncology (ASCO) in Chicago. Sznol, clinical research leader of the melanoma research program at Yale Cancer Center, was the senior author on the original study of combination immunotherapy that was first published in the New England Journal of Medicine and presented at ASCO in 2013 Continue reading

Responses with crizotinib in MET-amplified lung cancer show new targetable form of disease

Responses with crizotinib in MET-amplified lung cancer show new targetable form of disease

A study presented at the American Society of Clinical Oncology (ASCO) Annual Meeting 2014 reports the results of a first-in-human, phase 1 dose escalation trial of crizotinib (XALKORI) in 14 patients with advanced, MET-amplified non-small cell lung cancer (NCT00585195). In 2011, the drug crizotinib earned accelerated approval by the US FDA to target the subset of advanced non-small cell lung cancers caused by rearrangements of the anaplastic lymphoma kinase (ALK) gene, and subsequently was granted regular approval in 2013 Continue reading

One step closer to a breath test for lung cancer

One step closer to a breath test for lung cancer

Results of a University of Colorado Cancer Center study presented at the 50th Annual Meeting of the American Society for Clinical Oncology (ASCO) show that a test of organic compounds in exhaled breath can not only distinguish patients with lung cancer from patients with chronic obstructive pulmonary disease (COPD), but can also define the stage of any cancer present. Continue reading

One step closer to a breath test for lung cancer

One step closer to a breath test for lung cancer

Results of a University of Colorado Cancer Center study presented at the 50th Annual Meeting of the American Society for Clinical Oncology (ASCO) show that a test of organic compounds in exhaled breath can not only distinguish patients with lung cancer from patients with chronic obstructive pulmonary disease (COPD), but can also define the stage of any cancer present. Continue reading

Patients with metastatic colon cancer respond to new combination therapy

Patients with metastatic colon cancer respond to new combination therapy

In an aggressive disease known for poor response rates, researchers from The University of Texas MD Anderson Cancer Center found patients with advanced colorectal cancer responded well to a combination therapy of the drugs vermurafenib, cetuximab and irinotecan. Continue reading